{"id":"disitamab-vedotin-for-injection","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The antibody component of disitamab vedotin binds to EGFR on the surface of cancer cells, while the microtubule inhibitor component interferes with cell division, leading to cell death. This mechanism is particularly effective against EGFR-expressing tumors.","oneSentence":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:17.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07142200","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-09-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":45},{"nctId":"NCT07100184","phase":"PHASE2","title":"RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-09-01","conditions":"HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT","enrollment":30},{"nctId":"NCT06957561","phase":"PHASE1, PHASE2","title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Bladder Cancer, Muscle-invasive Bladder Cancer","enrollment":30},{"nctId":"NCT06734182","phase":"PHASE2","title":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-06-22","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT06663007","phase":"PHASE1, PHASE2","title":"RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-09-24","conditions":"Prostate Cancer, CDK12 Gene Mutation","enrollment":72},{"nctId":"NCT06378242","phase":"PHASE1, PHASE2","title":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-06-14","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":24},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT06155396","phase":"PHASE2","title":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-01-11","conditions":"Cervical Cancer","enrollment":116},{"nctId":"NCT05514158","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2022-09-28","conditions":"Gastric Cancer","enrollment":24},{"nctId":"NCT06074484","phase":"PHASE2","title":"A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-10","conditions":"Muscle Invasive Bladder Carcinoma","enrollment":36},{"nctId":"NCT06055153","phase":"PHASE1, PHASE2","title":"DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2023-09-30","conditions":"Esophageal Squamous Carcinoma, HER-2 Protein Overexpression","enrollment":20},{"nctId":"NCT05979740","phase":"PHASE2","title":"RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy","enrollment":6},{"nctId":"NCT05723991","phase":"PHASE4","title":"Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Chunguang yang (101937)","startDate":"2022-09-28","conditions":"Radical Cystectomy, Urothelial Carcinoma","enrollment":36},{"nctId":"NCT05488353","phase":"PHASE4","title":"A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-09-01","conditions":"Bladder Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RC48"],"phase":"phase_2","status":"active","brandName":"Disitamab Vedotin for injection","genericName":"Disitamab Vedotin for injection","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells. Used for Locally advanced or metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}